VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | Updates on belantamab mafodotin for myeloma

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, shares an update on the use of belantamab mafodotin, an anti-BCMA monoclonal antibody therapy, for the treatment of multiple myeloma. Dr Cerchione comments on the results of a real-world analysis of the efficacy and tolerability of belantamab mafodotin presented at the virtual European Hematology Association (EHA) Congress 2021, and outlines investigations of belantamab mafodotin in novel combinations, such as is being explored in the DREAMM-5 trial (NCT04126200). Dr Cerchione also discussess novel observations around the safety and tolerability of belantamab mafodotin from the real-world setting. This interview took place at the virtual EHA Congress 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter